...
search icon
virx-img

Viracta Therapeutics Inc, Common Stock

VIRX

PINK

$0.01

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$397.44K
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
228.98K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.28
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.01 L
$0.58 H
$0.01

About Viracta Therapeutics Inc, Common Stock

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVIRXSectorS&P500
1-Week Return-35.48%1.46%0.82%
1-Month Return-46.52%0.42%4.06%
3-Month Return-42.86%-0.4%17.27%
6-Month Return-94.27%-3.63%7.62%
1-Year Return-98%-7.49%12.5%
3-Year Return-99.76%4.53%62.86%
5-Year Return-99.89%34.6%98.95%
10-Year Return-100%79.56%199.05%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue2.07M120.00K---[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":5.79,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-32.00K178.00K210.00K492.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":6.5,"profit":true},{"date":"2021-12-31","value":36.18,"profit":true},{"date":"2022-12-31","value":42.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit2.07M88.00K(178.00K)(210.00K)(492.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":4.25,"profit":true},{"date":"2021-12-31","value":-8.59,"profit":false},{"date":"2022-12-31","value":-10.13,"profit":false},{"date":"2023-12-31","value":-23.73,"profit":false}]
Gross Margin100.00%73.33%(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":73.33,"profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses25.36M18.82M25.80M50.59M50.69M[{"date":"2019-12-31","value":50.03,"profit":true},{"date":"2020-12-31","value":37.12,"profit":true},{"date":"2021-12-31","value":50.89,"profit":true},{"date":"2022-12-31","value":99.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(23.29M)(18.82M)62.50M(50.59M)(50.69M)[{"date":"2019-12-31","value":-37.26,"profit":false},{"date":"2020-12-31","value":-30.1,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-80.94,"profit":false},{"date":"2023-12-31","value":-81.11,"profit":false}]
Total Non-Operating Income/Expense-(370.00K)(75.92M)1.99M(77.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-18.63,"profit":false},{"date":"2021-12-31","value":-3822.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-3.88,"profit":false}]
Pre-Tax Income(23.33M)(19.02M)(114.76M)(49.20M)(51.06M)[{"date":"2019-12-31","value":-2333000000,"profit":false},{"date":"2020-12-31","value":-1901700000,"profit":false},{"date":"2021-12-31","value":-11476200000,"profit":false},{"date":"2022-12-31","value":-4919700000,"profit":false},{"date":"2023-12-31","value":-5105800000,"profit":false}]
Income Taxes514.00K182.00K88.30M577.00K-[{"date":"2019-12-31","value":0.58,"profit":true},{"date":"2020-12-31","value":0.21,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.65,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes-(19.20M)(203.06M)(49.77M)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1919900000,"profit":false},{"date":"2021-12-31","value":-20306200000,"profit":false},{"date":"2022-12-31","value":-4977400000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations-(21.61M)(114.76M)(49.38M)(47.62M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2161000000,"profit":false},{"date":"2021-12-31","value":-11476200000,"profit":false},{"date":"2022-12-31","value":-4937500000,"profit":false},{"date":"2023-12-31","value":-4761900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(23.33M)(19.20M)(203.06M)(49.77M)(51.06M)[{"date":"2019-12-31","value":-2333000000,"profit":false},{"date":"2020-12-31","value":-1919900000,"profit":false},{"date":"2021-12-31","value":-20306200000,"profit":false},{"date":"2022-12-31","value":-4977400000,"profit":false},{"date":"2023-12-31","value":-5105800000,"profit":false}]
EPS (Diluted)(10.50)(5.59)(0.61)(1.30)(1.32)[{"date":"2019-12-31","value":-1050,"profit":false},{"date":"2020-12-31","value":-559,"profit":false},{"date":"2021-12-31","value":-61,"profit":false},{"date":"2022-12-31","value":-130,"profit":false},{"date":"2023-12-31","value":-132,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VIRX
Cash Ratio 0.74
Current Ratio 0.76

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VIRX
ROA (LTM) -66.76%
ROE (LTM) -370.13%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VIRX
Debt Ratio Lower is generally better. Negative is bad. 1.30
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.30

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VIRX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 3.00
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Viracta Therapeutics Inc share price today?

Viracta Therapeutics Inc (VIRX) share price today is $0.01

Can Indians buy Viracta Therapeutics Inc shares?

Yes, Indians can buy shares of Viracta Therapeutics Inc (VIRX) on Vested. To buy Viracta Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VIRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Viracta Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Viracta Therapeutics Inc (VIRX) via the Vested app. You can start investing in Viracta Therapeutics Inc (VIRX) with a minimum investment of $1.

How to invest in Viracta Therapeutics Inc shares from India?

You can invest in shares of Viracta Therapeutics Inc (VIRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in VIRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Viracta Therapeutics Inc shares
What is Viracta Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Viracta Therapeutics Inc (VIRX) is $0.58. The 52-week low price of Viracta Therapeutics Inc (VIRX) is $0.01.

What is Viracta Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Viracta Therapeutics Inc (VIRX) is 3.00

What is the Market Cap of Viracta Therapeutics Inc?

The market capitalization of Viracta Therapeutics Inc (VIRX) is $397.44K

What is Viracta Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Viracta Therapeutics Inc is VIRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top